Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit

Appendix Figure 2. The study with an excluded rate ratio had no events in either group. APRICOT-2 = Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2; ASPECT-2 = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2; ATACS = Antithrombotic Therapy in Acute Coronary Syndromes; OASIS = Organization to Assess Strategies for Ischemic Syndromes; WARIS II = Warfarin, Aspirin, Reinfarction Study.
Appendix Figure 2. The study with an excluded rate ratio had no events in either group. APRICOT-2 = Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2; ASPECT-2 = Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2; ATACS = Antithrombotic Therapy in Acute Coronary Syndromes; OASIS = Organization to Assess Strategies for Ischemic Syndromes; WARIS II = Warfarin, Aspirin, Reinfarction Study. Forest plot showing rate ratios of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting for warfarin plus aspirin compared with aspirin alone.

This Article

  1. Ann Intern Med August 16, 2005 vol. 143 no. 4 241-250
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. December 1, 2009, 151 (11)
  1. Alert me to current issues